We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
HDL Therapeutics announced positive data from the company's registrational trial for its investigational acute care therapeutic device, the PDS-2™ System, in patients with homozygous familial hypercholesterolemia (HoFH).